Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Theratechnologies
< Previous
1
2
Next >
Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025
September 17, 2024
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
Theratechnologies to Present at Upcoming Investor Conferences in September
September 09, 2024
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024
July 10, 2024
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update
June 26, 2024
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
May 23, 2024
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
Theratechnologies Reports on its Annual Meeting of Shareholders
May 09, 2024
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
May 02, 2024
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
April 15, 2024
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
April 11, 2024
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
April 10, 2024
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
April 08, 2024
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
Theratechnologies Appoints Elina Tea to its Board of Directors
April 05, 2024
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
April 03, 2024
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
March 28, 2024
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
Theratechnologies Announces Update on its Preclinical Oncology Research Program
March 22, 2024
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
Theratechnologies Appoints Jordan Zwick to its Board of Directors
March 21, 2024
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
March 21, 2024
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau
February 29, 2024
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA
February 27, 2024
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance
February 21, 2024
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
February 20, 2024
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
February 15, 2024
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
February 06, 2024
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
January 24, 2024
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application
January 23, 2024
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA
January 02, 2024
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose
December 13, 2023
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award
November 24, 2023
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
October 31, 2023
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
October 26, 2023
From
Theratechnologies
Via
GlobeNewswire
Tickers
THTX
TSX:TH
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.